GSK vs NBBK · P/E 13, $103.31B cap vs P/E 14, rev $335.7M
GlaxoSmithKline PLC ADR (GSK) versus NB Bancorp, Inc. Common Stock (NBBK) — a side-by-side from cached financials, not a winner call.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
NB Bancorp, Inc. Common Stock (NBBK) is a banks - regional company listed on US.
GSK does not have a complete income-statement cache yet.
Latest reported NBBK revenue for 2025-12-31 was $335.7M. Net income was $50.3M. Revenue was up 14.8% from 2024-12-31 to 2025-12-31. NBBK currently screens at market cap $863.3M and trailing P/E 14.4.
GSK currently screens at market cap $103.31B and trailing P/E 13.5. NBBK currently screens at market cap $863.3M and trailing P/E 14.4.
Not investment advice. Open the GSK and NBBK stock pages for the full models.
Not investment advice.